RESUMO
Among the variety of cardiologic pharmacological therapy options, beta-blockers stand on a prominent position. There are several reasons for this. On one hand they have numerous indication rounds, even though professional guidelines have recently tended to de-emphasize them for treatments of hypertension without complication or comorbidity. However, in addition to hypertonic cases associated with cardiac complication, they play a fundamental role in treating heart failure and arrhythmia and the different clinical manifestations (stable angina pectoris, myocardial state) of ischemic heart disease. The decade long development of the pharmacological group made its hemodynamic effects ever more refined. On the other hand we must not neglect the fact that more and more features came to light that positively influence the outcome of cardiovascular diseases. Verification of these latter features in numerous multicentric studies showed how to achieve a beneficial effect on survivability, independent on even hemodynamic effects during beta-blocker therapy.
Assuntos
Antagonistas Adrenérgicos beta/farmacologia , Anti-Hipertensivos/farmacologia , Carbazóis/farmacologia , Doenças Cardiovasculares/prevenção & controle , Hemodinâmica/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Propanolaminas/farmacologia , Antagonistas Adrenérgicos beta/farmacocinética , Antagonistas Adrenérgicos beta/uso terapêutico , Angina Pectoris/tratamento farmacológico , Anti-Hipertensivos/farmacocinética , Anti-Hipertensivos/uso terapêutico , Bisoprolol/farmacologia , Carbazóis/farmacocinética , Carbazóis/uso terapêutico , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/fisiopatologia , Carvedilol , Ensaios Clínicos como Assunto , Prescrições de Medicamentos/estatística & dados numéricos , Medicina Baseada em Evidências , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Hungria , Hipertensão/complicações , Hipertensão/metabolismo , Metoprolol/farmacologia , Estudos Multicêntricos como Assunto , Estresse Oxidativo/efeitos dos fármacos , Atenção Primária à Saúde/normas , Propanolaminas/farmacocinética , Propanolaminas/uso terapêutico , RiscoRESUMO
LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor in development for treatments of hypertension and heart failure indications. In 3 separate studies, pharmacokinetic drug-drug interactions (DDIs) potential was assessed when LCZ696 was coadministered with hydrochlorothiazide (HCTZ), amlodipine, or carvedilol. The studies used a open-label, single-sequence, 3-period, crossover design in healthy subjects. Blood samples were collected to determine the pharmacokinetic parameters of LCZ696 analytes (AHU377, LBQ657, and valsartan), HCTZ, amlodipine, or carvedilol (R[+]- and S[-]-carvedilol) for statistical analysis. When coadministered LCZ696 with HCTZ, the 90% CIs of the geometric mean ratios of AUCtau,ss of HCTZ and that of LBQ657 were within a 0.80-1.25 interval, whereas HCTZ Cmax,ss decreased by 26%, LBQ657 Cmax,ss increased by 19%, and the AUCtau,ss and Cmax,ss of valsartan increased by 14% and 16%, respectively. Pharmacokinetics of amlodipine, R(+)- and S(-)-carvedilol, or LBQ657 were not altered after coadministration of LCZ696 with amlodipine or carvedilol. Coadministration of LCZ696 400 mg once daily (qd) with HCTZ 25 mg qd, amlodipine 10 mg qd, or carvedilol 25 mg twice a day (bid) had no clinically relevant pharmacokinetic drug-drug interactions. LCZ696, HCTZ, amlodipine, and carvedilol were safe and well tolerated when given alone or concomitantly in the investigated studies.
Assuntos
Antagonistas Adrenérgicos beta/farmacocinética , Aminobutiratos/farmacocinética , Anlodipino/farmacocinética , Antagonistas de Receptores de Angiotensina/farmacocinética , Anti-Hipertensivos/farmacocinética , Bloqueadores dos Canais de Cálcio/farmacocinética , Carbazóis/farmacocinética , Diuréticos/farmacocinética , Hidroclorotiazida/farmacocinética , Neprilisina/antagonistas & inibidores , Propanolaminas/farmacocinética , Inibidores de Proteases/farmacocinética , Tetrazóis/farmacocinética , Administração Oral , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/efeitos adversos , Antagonistas Adrenérgicos beta/sangue , Adulto , Aminobutiratos/administração & dosagem , Aminobutiratos/efeitos adversos , Aminobutiratos/sangue , Anlodipino/administração & dosagem , Anlodipino/efeitos adversos , Anlodipino/sangue , Antagonistas de Receptores de Angiotensina/administração & dosagem , Antagonistas de Receptores de Angiotensina/efeitos adversos , Antagonistas de Receptores de Angiotensina/sangue , Anti-Hipertensivos/administração & dosagem , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/sangue , Área Sob a Curva , Arizona , Compostos de Bifenilo , Bloqueadores dos Canais de Cálcio/administração & dosagem , Bloqueadores dos Canais de Cálcio/efeitos adversos , Bloqueadores dos Canais de Cálcio/sangue , Carbazóis/administração & dosagem , Carbazóis/efeitos adversos , Carbazóis/sangue , Carvedilol , Estudos Cross-Over , Diuréticos/administração & dosagem , Diuréticos/efeitos adversos , Diuréticos/sangue , Esquema de Medicação , Combinação de Medicamentos , Interações Medicamentosas , Quimioterapia Combinada , Feminino , Voluntários Saudáveis , Humanos , Hidroclorotiazida/administração & dosagem , Hidroclorotiazida/efeitos adversos , Hidroclorotiazida/sangue , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Modelos Biológicos , Neprilisina/metabolismo , Propanolaminas/administração & dosagem , Propanolaminas/efeitos adversos , Propanolaminas/sangue , Inibidores de Proteases/administração & dosagemRESUMO
Carvedilol is an anti-hypertensive agent capable of blocking both alph (α) and beta (ß) receptors used to preclude cardiac arrhythmias and angina. The study was designed to evaluate the Pharmacokinetics of carvedilol in human male and female volunteers. Healthy male and female (twenty each) volunteers were finalized for the study after preliminarily clinical examination. Blood samples were collected at specific time intervals after giving an oral dose of 12.5mg carvedilol, separated the plasma and placed at -80°C until analysis. Estimation of carvedilol in human plasma was accomplished by High performance liquid chromatographic (HPLC) method using fluorescent detector. Plasma concentration-time curve was used for calculation of pharmacokinetic parameters using two-compartment open model. Mean (SD) values of AUC and Cmax 0.076±0.021ßg.h/ml and 0.024±0.005ßg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042ßg.h/ml and 0.048±0.02ßg/mL, respectively). Overall, bioavailability of carvedilol was somewhat higher in females than in males, but these differences could be expounded by the lower body weight of female. Conversely, no significant differences were found for tmax, clearance and half-life in male and female. Moreover the ethnicity had significant impact on the Pharmacokinetics of carvedilol in human.
Assuntos
Carbazóis/farmacocinética , Propanolaminas/farmacocinética , Adulto , Carvedilol , Cromatografia Líquida de Alta Pressão , Feminino , Humanos , Masculino , Caracteres SexuaisRESUMO
In the present study we have developed a simple, time, and cost effective in vivo rodent protocol to screen the susceptibility of a test compound for P-glycoprotein (P-gp) mediated efflux at the blood brain barrier (BBB) during early drug discovery. We used known P-gp substrates as test compounds (quinidine, digoxin, and talinolol) and elacridar (GF120918) as a chemical inhibitor to establish the model. The studies were carried out in both mice and rats. Elacridar was dosed intravenously at 5 mg/kg, 0.5 h prior to probe substrate administration. Plasma and brain samples were collected and analyzed using UPLC-MS/MS. In the presence of elacridar, the ratio of brain to plasma area under the curve (B/P) in mouse increased 2, 4, and 38-fold, respectively, for talinolol, digoxin, and quinidine; whereas in rat, a 70-fold increase was observed for quinidine. Atenolol, a non P-gp substrate, exhibited poor brain penetration in the presence or absence of elacridar in both species (B/P ratio ~ 0.1). Elacridar had no significant effect on the systemic clearance of digoxin or quinidine; however, a trend towards increasing volume of distribution and half life was observed. Our results support the utility of elacridar in evaluation of the influence of P-gp mediated efflux on drug distribution to the brain. Our protocol employing a single intravenous dose of elacridar and test compound provides a cost effective alternative to expensive P-gp knockout mice models during early drug discovery.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Acridinas/farmacologia , Barreira Hematoencefálica/metabolismo , Encéfalo/metabolismo , Tetra-Hidroisoquinolinas/farmacologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Acridinas/administração & dosagem , Animais , Área Sob a Curva , Transporte Biológico , Cromatografia Líquida , Análise Custo-Benefício , Digoxina/farmacocinética , Desenho de Fármacos , Interações Medicamentosas , Meia-Vida , Injeções Intravenosas , Masculino , Camundongos , Propanolaminas/farmacocinética , Quinidina/farmacocinética , Ratos , Ratos Sprague-Dawley , Espectrometria de Massas em Tandem , Tetra-Hidroisoquinolinas/administração & dosagem , Fatores de Tempo , Distribuição TecidualRESUMO
Drug-induced kidney injury (DIKI) results in attrition during drug development; new DIKI urinary biomarkers offer potential to detect and monitor DIKI progression and regression, but frequently only in rats. The triple reuptake inhibitor (TRI) PRC200-SS represents a new class of antidepressants that elevate synaptic levels of serotonin, norepinephrine, and dopamine and is expected to produce more rapid onset and better antidepressant efficacy than single or dual inhibitors. Although preclinical studies and recent clinical trials lend support to this concept of superior efficacy for TRIs, there is little information on the safety profile of this class of compounds. Using histopathology and DIKI biomarkers, in single- and repeat dose toxicological studies in cynomolgus monkeys, PRC200-SS demonstrated dose-proportional kidney toxicity. Characterization of the histopathological lesions, using a combination of immunohistochemistry (IHC) and urinary biomarker analysis, indicated that the compound is a distal tubule and collecting duct toxicant. Segment specificity for the lesions was shown using a newly developed triple IHC combination method with antibodies against calbindin D28, aquaporin 2, and aquaporin 1. Urinary biomarker analyses, using multiplex immunoassays, confirmed a dose-proportional increase in the excretion of calbindin D28 and clusterin in compound-treated monkeys with levels returning to baseline during the drug-free recovery period. These results constitute the validation of distal nephron DIKI biomarkers in the cynomolgus monkey and demonstrate the utility of calbindin D28 and clusterin to monitor the progression of distal nephron DIKI, representing potential early biomarkers of DIKI for the clinic.
Assuntos
Antidepressivos/toxicidade , Biomarcadores , Nefropatias/induzido quimicamente , Naftalenos/toxicidade , Inibidores da Captação de Neurotransmissores/toxicidade , Propanolaminas/toxicidade , Animais , Antidepressivos/farmacocinética , Biomarcadores/sangue , Biomarcadores/urina , Biotransformação , Células Cultivadas , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Feminino , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Imuno-Histoquímica , Nefropatias/sangue , Nefropatias/patologia , Nefropatias/urina , Macaca fascicularis , Masculino , Naftalenos/farmacocinética , Inibidores da Captação de Neurotransmissores/farmacocinética , Tamanho do Órgão/efeitos dos fármacos , Projetos Piloto , Propanolaminas/farmacocinéticaRESUMO
Aminomethyl propanol and aminomethyl propanediol are substituted aliphatic alcohols that function as pH adjusters in cosmetic products at concentrations less than 10%; additionally, aminomethyl propanediol is a fragrance. Extensive oral toxicity data are reviewed, with fewer inhalation toxicity data. Dermal toxicity data are presented that demonstrate, for example, that a mascara with 1.92% aminomethyl propanediol does not cause dermal irritation or allergic contact sensitization, suggesting that the maximum reported use concentration of 2% in mascara would be safe. Although these ingredients are primary amines that are not substrates for N-nitrosation, they may contain secondary amines as impurities in finished products that may undergo N-nitrosation. These ingredients should not be included in cosmetic formulations containing N-nitrosating agents. The Cosmetic Ingredient Review Expert Panel concludes that aminomethyl propanol and aminomethyl propanediol are safe as cosmetic ingredients in the practices of use and concentrations as described in this safety assessment.
Assuntos
Qualidade de Produtos para o Consumidor , Cosméticos/química , Emulsificantes/toxicidade , Propanolaminas/toxicidade , Propilenoglicóis/toxicidade , Administração Cutânea , Administração por Inalação , Administração Oral , Animais , Soluções Tampão , Cosméticos/toxicidade , Emulsificantes/administração & dosagem , Emulsificantes/farmacocinética , Humanos , Hipersensibilidade/etiologia , Dose Letal Mediana , Odorantes , Propanolaminas/administração & dosagem , Propanolaminas/farmacocinética , Propilenoglicóis/administração & dosagem , Propilenoglicóis/farmacocinética , Testes de ToxicidadeRESUMO
INTRODUCTION: The aim of the work was to establish the impact of urethane-chloralose anaesthesia on pharmacokinetic-pharmacodynamic (PK-PD) properties of carvedilol in control rats and L-NAME hypertensive animals. METHODS: Male Wistar Rats were randomly divided into: control (n=12) with tap water to drink and L-NAME rats (n=12) with L-NAME solution (40 mg/kg/day) to drink for 2 weeks. Effects of carvedilol (1 mg kg(-1), i.v.) on blood pressure and heart rate were recorded during 3 h in conscious and urethane (500 mg kg(-1), i.p.) - chloralose (50 mg kg(-1), i.p.) anaesthetized rats. Carvedilol plasma pharmacokinetics was studied by means of traditional blood sampling. PK-PD modeling of carvedilol was made by means of an effect compartment model. RESULTS: Neither urethane-chloralose nor L-NAME modified estimation of pharmacokinetic parameters of carvedilol. Although urethane-chloralose did not modify potency of carvedilol comparing with awake animals in control and hypertensive group, maximal negative chronotropic response was significantly greater in anaesthetized L-NAME rats in comparison to awake animals. Conversely, anaesthesia did not modify maximal chronotropic response to carvedilol in control rats. Whilst no differences were found in the estimated potency of carvedilol hypotensive response comparing control and L-NAME rats in both awake and anaesthetized conditions, maximal hypotensive effect of carvedilol was significantly greater in anaesthetized control and L-NAME animals in comparison to conscious rats. L-NAME rats showed a greater maximal hypotensive response comparing to control group. DISCUSSION: Urethane-chloralose anaesthesia is an acceptable experimental condition for the evaluation of PK-PD properties of carvedilol, considering that it does not affect the potency of carvedilol for its chronotropic and hypotensive effect. Conclusions obtained from urethane-chloralose anaesthetized animals, regarding the impact of l-NAME treatment on PK-PD properties of carvedilol, did not differ from those obtained from conscious animals. Anaesthesia did not modify pharmacokinetic behaviour of carvedilol in both normotensive and L-NAME hypertensive rats.
Assuntos
Antagonistas Adrenérgicos beta/farmacocinética , Anestesia , Carbazóis/farmacocinética , Cloralose/farmacocinética , Propanolaminas/farmacocinética , Uretana/farmacocinética , Administração Oral , Antagonistas Adrenérgicos beta/administração & dosagem , Antagonistas Adrenérgicos beta/sangue , Algoritmos , Animais , Área Sob a Curva , Pressão Sanguínea/efeitos dos fármacos , Carbazóis/administração & dosagem , Carbazóis/sangue , Carvedilol , Cloralose/administração & dosagem , Interpretação Estatística de Dados , Modelos Animais de Doenças , Esquema de Medicação , Sinergismo Farmacológico , Meia-Vida , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/induzido quimicamente , Injeções Intraperitoneais , Injeções Intravenosas , Masculino , Modelos Biológicos , NG-Nitroarginina Metil Éster/efeitos adversos , NG-Nitroarginina Metil Éster/química , Propanolaminas/administração & dosagem , Propanolaminas/sangue , Ratos , Ratos Wistar , Soluções/química , Uretana/administração & dosagemRESUMO
The ability of various human derived in vitro systems to predict various aspects of the in vivo metabolism and kinetics of almokalant have been investigated in a multicenter collaborative study. Although almokalant has been withdrawn from further clinical development, its metabolic and pharmacokinetic properties have been well characterized. Studies with precision-cut liver slices, primary hepatocyte cultures, and hepatic microsomal fractions fortified with UDP-glucuronic acid all suggested that almokalant is mainly glucuronidated to the stereoisomers M18a and M18b, which is in good agreement with the results in vivo. Both in vivo and in vitro studies indicate that the formation of M18b dominates over that of M18a, although the difference is more pronounced with the in vitro systems. Molecular modeling, cDNA-expressed enzyme analysis, correlation analysis, and inhibition studies did not clearly indicate which P450 enzymes catalyze the oxidative pathways, which may indicate a problem in identifying responsible enzymes for minor metabolic routes by in vitro methods. All of the in vitro systems underpredicted the metabolic clearance of almokalant, which has previously been reported to be a general problem for drugs that are cleared by P450-dependent metabolism. Although few studies on in vivo prediction of primarily glucuronidated drugs have appeared, in vitro models may consistently underpredict in vivo metabolic clearance. We conclude that in vitro systems, which monitor phase II metabolism, would be beneficial for prediction of the in vivo metabolism, although all of the candidate liver-derived systems studied here, within their intrinsic limitations, provided useful information for predicting metabolic routes and rates.